# VLA15

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/vla15
Canonical HTML page: https://getbiobrief.com/entity/vla15

## Timeline

- **2027**: Potential Launch — Anticipated commercial availability following regulatory approval and CDC recommendation.
- **2026-Q4**: Regulatory Filing — Expected submission of Biologics License Application (BLA) to the FDA.
- **2026-03-25**: Efficacy Results — Trial data shows over 70% efficacy against Lyme disease in endemic regions.
- **2022-08-01**: Phase 3 Initiation — Pfizer and Valneva launch the VALOR Phase 3 clinical trial for VLA15.

## Recent coverage (1 stories)

### Pfizer's Lyme Vaccine Shows Over 70% Efficacy in Pivotal Phase 3 Trial
2026-03-25 02:03:00 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Pfizer and Valneva have reported positive Phase 3 results for their Lyme disease vaccine candidate, VLA15, demonstrating an efficacy rate exceeding 70%. This development marks a significant milestone in addressing the growing public health threat of tick-borne illnesses, potentially offering the first preventative vaccine for the disease in over two decades.
Full story: https://getbiobrief.com/story/pfizer-lyme-disease-vaccine-phase-3-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.